Lupin has reported results for the year ended March 31, 2013.
For the year, the company’s net profit grew by 56.70% at Rs 1260.43 crore as compared to Rs 804.37 crore for the year ended March 31, 2012. Its total income has increased by 32.61% to Rs 7145.82 crore for the year from Rs 5388.32 crore for the previous year.
On consolidated basis, the group’s net profit after taxes, minority interest stood at Rs 1314.16 crore for the FY13 as compared to Rs 867.65 crore in FY12, up by 51.46%. Groups’s total income has increased by 36.24% to Rs 9669.15 crore for the year under review from Rs 7097.26 crore for the previous year.
Lupin’s board of directors at its meeting held on May 08, 2013, inter alia, has recommended dividend at the rate of 200% i.e. Rs 4 per equity shares of the face value of Rs 2 each for the year ended March 31, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1935.25 |
| Dr. Reddys Labs. | 1245.50 |
| Cipla | 1438.75 |
| Zydus Lifesciences | 1150.50 |
| Lupin | 2496.05 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: